Shares of Moderna, Inc. (MRNA) plummeted 12.47% in intraday trading on Tuesday, following news that the U.S. Food and Drug Administration (FDA) has named oncologist Vinay Prasad as its top vaccine official. Dr. Prasad, known for his critical stance on certain vaccine policies, has sparked concerns among investors about potential changes in vaccine regulation and approval processes.
The appointment of Dr. Prasad appears to have sent shockwaves through the vaccine industry, with other major players also experiencing significant drops. Pfizer fell 3.3% and Novavax declined 6.3% in sympathy with Moderna's steep decline. This market reaction underscores the sensitivity of vaccine stocks to regulatory developments and leadership changes within key health agencies.
Moderna's sharp decline continues a challenging year for the company. The stock is now down 41.37% year-to-date and has fallen a staggering 94.97% from its all-time closing high of $484.47 reached on August 9, 2021. At its current trading level, Moderna is on track to close at its lowest point since March 13, 2020, highlighting the dramatic reversal of fortune for the once high-flying COVID-19 vaccine maker.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。